Gamma Knife Market Size By Range (High-end Gamma Knife, Medium Gamma Knife, Low Gamma Knife), By Indication (Head & Neck Cancer, Brain Metastases, Malignant Tumors), By End-use (Hospitals, Radiotherapy Centers), & Forecast, 2023 – 2032

Gamma Knife Market Size

Gamma Knife Market size was valued at around USD 479 million in 2022 and is estimated to reach over USD 921 million by 2032. This market revenue is attributable to the various factors comprising the increasing prevalence of neurological disorders, expanding applications, rising investment in healthcare infrastructure, and technological advancements among others.
 

The rising incidence of brain tumors, arteriovenous malformations (AVMs), and other neurological conditions has contributed to the growth of the market. As per the American Society of Clinical Oncology, in 2020, an estimated 308,102 people were diagnosed with a primary brain or spinal cord tumor worldwide. Gamma knife radiosurgery is a non-invasive treatment option that has gained popularity due to its effectiveness and minimal side effects.
 

Patients and healthcare providers are increasingly preferring minimally invasive treatment options that offer shorter recovery times and reduced risks compared to traditional open surgeries. Furthermore, governments and healthcare organizations are investing in upgrading their healthcare infrastructure, including the installation of advanced medical equipment. This has created opportunities for the market, as hospitals and specialized clinics emphasizing investing in gamma knife systems to provide state-of-the-art treatment options for their patients.

Gamma Knife is a non-invasive medical device used in stereotactic radiosurgery (SRS) to treat certain brain conditions and disorders. It is a precise and highly focused radiation therapy system designed to deliver a concentrated dose of gamma rays to a specific target within the brain.
 

However, the changing regulations related to medical equipment may act as a barrier to the  market progression. Several organizations and governments dictate guidelines and rules for the safer and more effective employment of such devices. The regulatory changes may lead to penalties and loss of market access in a global marketplace. New medical devices regulations from the European Union (EU), Canada, and the U.S. were implemented simultaneously that impacted the companies' bottom lines. The International Organization for Standardization (ISO), the European Union (EU), and a group of countries have adopted the Medical Device Single Audit Program (MDSAP).
 

This MDSAP has several disadvantages such as regulatory bodies that are permitted to conduct unannounced inspections based on problems, they spotted comprising recalls, significant complaints as well as special audits. Some organizations have full time staff to assist with inspections and audits that become stressful for the companies, thereby increasing the complexity of the product approval procedure.
 

COVID-19 Impact

The COVID-19 pandemic had had a negative impact on the gamma knife market. During the pandemic, many hospitals and healthcare facilities had to prioritize resources to accommodate the influx of COVID-19 patients. This led to the postponement or rescheduling of elective procedures including gamma knife surgeries. As a result, the demand for gamma knife systems had been temporarily reduced. The global healthcare industry faced supply chain disruptions due to lockdown measures, travel restrictions, and increased demand for medical equipment. These disruptions had affected the production and delivery of gamma knife systems, leading to delays in installations or equipment upgrades.
 

However, in 2021, the technological advancements and incorporation of advanced imaging techniques have augmented target disease diagnosis and treatment compliance and promoted the acceptance of products. In addition, some of the procedures if not performed on time may lead to the death of patients. Hence, despite the coronavirus crisis, such emergency procedures were performed in healthcare facilities across the world. These factors helped to uplift the market share. Thus, the COVID-19 pandemic has slightly affected the market in the shorter run; however, the reduced COVID-19 infection rates & patients and rising procedural volume facilitated the market growth.
 

Gamma Knife Market Trends

Gamma knife have witnessed significant technological advancements in recent years. These advancements are intended to improve the accuracy and effectiveness of neurological diseases treatment options. Integrated imaging systems are allowing on-site imaging, such as magnetic resonance imaging (MRI), computed tomography (CT), or angiography, to be performed within the same facility as the gamma knife unit. This integration enables better treatment planning and real-time monitoring during procedures.
 

In some cases, fractionated gamma knife radiosurgery is employed to deliver the radiation dose over multiple treatment sessions instead of a single session. This approach may be beneficial for larger or irregularly shaped tumors or lesions. Advanced treatment planning software are allowing better visualization of tumors, improved dose optimization, and increased efficiency in treatment delivery. These advancements have enhanced treatment outcomes and reduced treatment times. Some gamma knife models are also incorporating motion management techniques to compensate for patient movement during treatment. This is particularly important for tumors located in areas affected by respiratory or cranial motion. Overall, technological advancements hold promise in improving target disease diagnosis & treatment procedures efficiently.
 

Gamma Knife Market Analysis

Based on range, the gamma knife market is segmented as high-end gamma knife, medium gamma knife, and low gamma knife. The high-end gamma knife segment was valued at over USD 201 million in 2022. This segmental share is attributable to the several benefits associated with the high-end gamma knife devices in treating various conditions in the brain. This device uses highly focused radiation beams to target specific areas in the brain with exceptional precision. This accuracy helps minimizing exposure to surrounding healthy tissues, reducing the risk of damage to critical structures, and lessening side effects. According to the research studies, gamma Knife has shown excellent long-term effectiveness in treating certain conditions, particularly brain tumors and arteriovenous malformations (AVMs).
 

It offers a high rate of tumor control and AVM obliteration, leading to improved outcomes and increased survival rates for patients. Similarly, patients experience minimal discomfort and have a relatively quick recovery time compared to traditional surgery. As a result, several benefits related to high-end gamma knife are expected to augment the business revenue.
 

Based on indication, the gamma knife market is segmented as head & neck cancer, arteriovenous malformations, brain metastases, malignant tumors, trigeminal neuralgia, and others. The brain metastases segment was valued at around USD 154 million in 2022. The segment has recorded the significant share in recent years due to advancements in technology, increased awareness related to early-stage disease diagnosis, etc. Gamma knife is allowing the precise delivery of a high dose of radiation to the tumor while minimizing exposure to nearby critical structures. This high-dose treatment can effectively control the growth of brain metastases and reduce the risk of recurrence.
 

In many cases, gamma knife radiosurgery can be completed in a single treatment session. This ability to complete treatment in a shorter time frame compared to traditional radiation therapy is advantageous for patients, as it minimizes the inconvenience and potential side effects associated with multiple treatment sessions. Moreover, gamma knife radiosurgery is a reliable treatment option for patients with brain metastases that are inoperable due to factors such as tumor size, location, or the presence of multiple tumors. It provides a non-invasive alternative for those that are not suitable candidates for surgical resection.
 

Based on end-use, the gamma knife market is segmented as hospitals, specialty clinics, radiotherapy centers, and others. The hospitals segment is projected to reach more than USD 421 million by the end of 2032. Hospitals play a crucial role in the treatment of neurological disorders and offer several advantages for patients. Hospitals commonly have multidisciplinary teams consisting of various healthcare professionals including oncologists, radiologists, pathologists, and nurses among others. This collaborative approach ensures that patients receive comprehensive and integrated care from experts in different specialties, leading to improved outcomes.
 

Hospitals often have access to advanced medical technologies, equipment, and infrastructure required for the diagnosis and treatment of cancer & neurological ailments. This includes cutting-edge imaging techniques, radiotherapy machines, and specialized laboratories, enabling accurate diagnosis and personalized treatment options. Similarly, hospitals offer a range of supportive care services to enhance the overall well-being of patients. These services may include psychological counselling, pain management, nutritional guidance, rehabilitation, and support groups.
 

U.S. gamma knife market is anticipated to expand at a considerable pace to reach around USD 298 million by 2032. This dominant share is attributable to the various factors such as advanced healthcare infrastructure, high healthcare spending, and a strong emphasis on technological advancements in medical devices among others. The country has witnessed the adoption of gamma knife technology in various leading medical centers and hospitals. Technological advancements in gamma knife systems, such as integrated imaging and treatment planning software have also contributed to market expansion.
 

Brain tumor is a significant health concern in the U.S., and the demand for effective treatment options has driven the growth of the market in the country. Access to adequate reimbursement for target disease treatment procedures encourages the adoption of advanced medical devices. Moreover, ongoing R&D activities focused on improving treatment outcomes and reducing side effects have led to the introduction of new and more advanced gamma knife equipments.
 

Gamma knife Market Share

Some of the major market players operating in the gamma knife market are

• Accuray Incorporated
• Akesis Inc.
• Elekta AB
• MASEP Medical Science Technology Development (Shenzhen)
• Mitsubishi Electric Corporation
• Varian Medical Systems

Major market players are adopting strategic formulations such as forward integration, new product development, geographical expansion, and research collaborations to garner maximum industry share and promote company growth.
 

Gamma Knife Industry News:

• In May 2022, Elekta launched new radiosurgery system, Elekta Esprit. This next-generation gamma knife enable more personalized radiosurgery with sub-millimeter accuracy and treatment planning in less than 60 seconds. Esprit also offers clinicians superior visualization, as well as remote accessibility and collaboration tools for the treatment team. This product launch helped the company in augmenting its gamma knife product portfolio.
   
• In September 2019, Akesis Galaxy SRS System received the FDA clearance. This Gamma stereotactic radiosurgery system offers continuous 360-degree rotation for high-precision intracranial treatments. The system is an ideal solution for high-throughput institutions, smaller cancer centers and value-based reimbursement models. Hence, this U.S. FDA approval assisted the company in strengthening its market presence in the U.S.
   

Gamma knife market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD (million) and volume (units) from 2018 to 2032 for the following segments:

Click here to Buy Section of this Report

By Range, 2018 - 2032 (USD Million & Units)

• High-end Gamma Knife
• Medium Gamma Knife
• Low Gamma Knife

By Indication, 2018 - 2032 (USD Million)

• Head & Neck Cancer
• Arteriovenous Malformations
• Brain Metastases
• Malignant tumors
• Trigeminal Neuralgia
• Others

By End-use, 2018 - 2032 (USD Million)

• Hospitals
• Specialty Clinics
• Radiotherapy Centers
• Others

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Poland
  • Switzerland
  • The Netherlands
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Indonesia
  • Philippines
  • Vietnam
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Chile
  • Colombia
  • Peru
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Iran
  • Turkey